1. Scrip
  2. >>Business

Intercept, Madrigal Get Ready For NASH Commercialization

 
• By Joseph Haas

With a 22 June US FDA action date for obeticholic acid in non-alcoholic steatohepatitis, Intercept is thinking ahead to launch plans. Madrigal said it plans a Q2 filing for its NASH drug and hopes to find an ex-US commercial partner.

liver
Intercept, Madrigal may be heading toward approval in NASH

Intercept Pharmaceuticals, Inc. is getting ready once again – after a roughly three-year interruption – for commercialization of potentially the first approved non-alcoholic steatohepatitis (NASH) drug, as the user fee date for obeticholic acid (OCA) approaches. The company expects a US Food and Drug Administration advisory committee review of its new drug application a few weeks before the 22 June action date and told shareholders on 2 March that it thinks marketing of OCA in primary biliary cholangitis (PBC) will give it a head start on reaching the right clinicians in NASH.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.

Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

 
• By Mandy Jackson

Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.

Amgen Under Pressure, But Seeing Gains Ahead Of Obesity Readouts

 
• By Mandy Jackson

MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.